JP2008531647A - 抗腫瘍作用を有する製剤 - Google Patents
抗腫瘍作用を有する製剤 Download PDFInfo
- Publication number
- JP2008531647A JP2008531647A JP2007557486A JP2007557486A JP2008531647A JP 2008531647 A JP2008531647 A JP 2008531647A JP 2007557486 A JP2007557486 A JP 2007557486A JP 2007557486 A JP2007557486 A JP 2007557486A JP 2008531647 A JP2008531647 A JP 2008531647A
- Authority
- JP
- Japan
- Prior art keywords
- angiogenesis
- antitumor activity
- defibrotide
- tumor
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000000259 anti-tumor effect Effects 0.000 title claims abstract 5
- 239000000203 mixture Substances 0.000 title claims description 4
- 238000009472 formulation Methods 0.000 title claims 3
- 238000000034 method Methods 0.000 claims abstract description 17
- 229940124276 oligodeoxyribonucleotide Drugs 0.000 claims abstract description 7
- 238000000605 extraction Methods 0.000 claims abstract description 5
- 241001465754 Metazoa Species 0.000 claims abstract description 4
- 210000000056 organ Anatomy 0.000 claims abstract description 3
- 239000004480 active ingredient Substances 0.000 claims abstract 3
- JNWFIPVDEINBAI-UHFFFAOYSA-N [5-hydroxy-4-[4-(1-methylindol-5-yl)-5-oxo-1H-1,2,4-triazol-3-yl]-2-propan-2-ylphenyl] dihydrogen phosphate Chemical group C1=C(OP(O)(O)=O)C(C(C)C)=CC(C=2N(C(=O)NN=2)C=2C=C3C=CN(C)C3=CC=2)=C1O JNWFIPVDEINBAI-UHFFFAOYSA-N 0.000 claims description 16
- 229960004120 defibrotide Drugs 0.000 claims description 15
- 230000000694 effects Effects 0.000 claims description 8
- 108091034117 Oligonucleotide Proteins 0.000 claims description 5
- 241000124008 Mammalia Species 0.000 claims description 3
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 claims description 3
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 claims description 3
- 229960002930 sirolimus Drugs 0.000 claims description 3
- 238000002360 preparation method Methods 0.000 claims 4
- DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 claims 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims 1
- 229930012538 Paclitaxel Natural products 0.000 claims 1
- 239000007864 aqueous solution Substances 0.000 claims 1
- QPNKYNYIKKVVQB-UHFFFAOYSA-N crotaleschenine Natural products O1C(=O)C(C)C(C)C(C)(O)C(=O)OCC2=CCN3C2C1CC3 QPNKYNYIKKVVQB-UHFFFAOYSA-N 0.000 claims 1
- 229960004397 cyclophosphamide Drugs 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- QVCMHGGNRFRMAD-XFGHUUIASA-N monocrotaline Chemical compound C1OC(=O)[C@](C)(O)[C@@](O)(C)[C@@H](C)C(=O)O[C@@H]2CCN3[C@@H]2C1=CC3 QVCMHGGNRFRMAD-XFGHUUIASA-N 0.000 claims 1
- QVCMHGGNRFRMAD-UHFFFAOYSA-N monocrotaline Natural products C1OC(=O)C(C)(O)C(O)(C)C(C)C(=O)OC2CCN3C2C1=CC3 QVCMHGGNRFRMAD-UHFFFAOYSA-N 0.000 claims 1
- 229960001592 paclitaxel Drugs 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims 1
- 230000033115 angiogenesis Effects 0.000 abstract description 21
- 206010028980 Neoplasm Diseases 0.000 abstract description 17
- 206010006187 Breast cancer Diseases 0.000 abstract description 3
- 208000026310 Breast neoplasm Diseases 0.000 abstract description 3
- 208000034578 Multiple myelomas Diseases 0.000 abstract description 3
- 206010035226 Plasma cell myeloma Diseases 0.000 abstract description 3
- 230000001419 dependent effect Effects 0.000 abstract description 3
- 239000002246 antineoplastic agent Substances 0.000 abstract 1
- 210000002889 endothelial cell Anatomy 0.000 description 11
- 238000004458 analytical method Methods 0.000 description 10
- 210000005166 vasculature Anatomy 0.000 description 7
- 230000015572 biosynthetic process Effects 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- 210000004443 dendritic cell Anatomy 0.000 description 5
- 108010082117 matrigel Proteins 0.000 description 5
- 108010013238 70-kDa Ribosomal Protein S6 Kinases Proteins 0.000 description 3
- 230000002491 angiogenic effect Effects 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004204 blood vessel Anatomy 0.000 description 3
- 210000002358 circulating endothelial cell Anatomy 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 210000004924 lung microvascular endothelial cell Anatomy 0.000 description 3
- 210000004925 microvascular endothelial cell Anatomy 0.000 description 3
- 210000004088 microvessel Anatomy 0.000 description 3
- 230000004614 tumor growth Effects 0.000 description 3
- 108010047303 von Willebrand Factor Proteins 0.000 description 3
- 102100036537 von Willebrand factor Human genes 0.000 description 3
- 229960001134 von willebrand factor Drugs 0.000 description 3
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 description 2
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 2
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 description 2
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 2
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 230000003511 endothelial effect Effects 0.000 description 2
- 230000035784 germination Effects 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 210000001616 monocyte Anatomy 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 238000011476 stem cell transplantation Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010054218 Factor VIII Proteins 0.000 description 1
- 102000001690 Factor VIII Human genes 0.000 description 1
- 101000990902 Homo sapiens Matrix metalloproteinase-9 Proteins 0.000 description 1
- 101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 102000043136 MAP kinase family Human genes 0.000 description 1
- 108091054455 MAP kinase family Proteins 0.000 description 1
- 102000007651 Macrophage Colony-Stimulating Factor Human genes 0.000 description 1
- 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 102100030412 Matrix metalloproteinase-9 Human genes 0.000 description 1
- 102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 description 1
- 206010029113 Neovascularisation Diseases 0.000 description 1
- 102100024616 Platelet endothelial cell adhesion molecule Human genes 0.000 description 1
- 108010094028 Prothrombin Proteins 0.000 description 1
- 102100027378 Prothrombin Human genes 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 1
- 102000016548 Vascular Endothelial Growth Factor Receptor-1 Human genes 0.000 description 1
- 108010053096 Vascular Endothelial Growth Factor Receptor-1 Proteins 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- -1 alkali metal salts Chemical class 0.000 description 1
- 230000000735 allogeneic effect Effects 0.000 description 1
- 239000004037 angiogenesis inhibitor Substances 0.000 description 1
- 230000001772 anti-angiogenic effect Effects 0.000 description 1
- 230000002253 anti-ischaemic effect Effects 0.000 description 1
- 230000002785 anti-thrombosis Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 210000002403 aortic endothelial cell Anatomy 0.000 description 1
- 238000002617 apheresis Methods 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000003527 fibrinolytic agent Substances 0.000 description 1
- 230000003480 fibrinolytic effect Effects 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 229940043355 kinase inhibitor Drugs 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 1
- 230000001023 pro-angiogenic effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 229940039716 prothrombin Drugs 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000005747 tumor angiogenesis Effects 0.000 description 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 1
- 210000003606 umbilical vein Anatomy 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT000336A ITMI20050336A1 (it) | 2005-03-03 | 2005-03-03 | Formulazione ad attivita' anti-tumorale |
| US73140405P | 2005-10-28 | 2005-10-28 | |
| PCT/EP2006/060306 WO2006094917A2 (en) | 2005-03-03 | 2006-02-27 | Oligodeoxyribonucleotides of 4000-10000 dalton for treating tumors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008531647A true JP2008531647A (ja) | 2008-08-14 |
| JP2008531647A5 JP2008531647A5 (enExample) | 2009-04-02 |
Family
ID=36572331
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007557486A Pending JP2008531647A (ja) | 2005-03-03 | 2006-02-27 | 抗腫瘍作用を有する製剤 |
| JP2007557485A Expired - Fee Related JP5714203B2 (ja) | 2005-03-03 | 2006-02-27 | 血管新生依存性腫瘍を治療するためのデフィブロチドおよび／またはオリゴデオキシリボヌクレオチド |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007557485A Expired - Fee Related JP5714203B2 (ja) | 2005-03-03 | 2006-02-27 | 血管新生依存性腫瘍を治療するためのデフィブロチドおよび／またはオリゴデオキシリボヌクレオチド |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US20080194506A1 (enExample) |
| EP (2) | EP1853277A1 (enExample) |
| JP (2) | JP2008531647A (enExample) |
| KR (3) | KR20070121001A (enExample) |
| AU (2) | AU2006222044A1 (enExample) |
| CA (2) | CA2598613A1 (enExample) |
| IL (3) | IL185182A0 (enExample) |
| MX (2) | MX2007010754A (enExample) |
| WO (2) | WO2006094917A2 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ITMI20031714A1 (it) | 2003-09-05 | 2005-03-06 | Gentium Spa | Formazioni ad azione antitumorale. |
| EP1982722A1 (en) * | 2007-04-16 | 2008-10-22 | Gentium S.p.A. | Use of oligotide for the treatment of renal diseases |
| EP2103689A1 (en) * | 2008-03-19 | 2009-09-23 | Gentium S.p.A. | Synthetic phosphodiester oligonucleotides and therapeutical uses thereof |
| US8187897B2 (en) | 2008-08-19 | 2012-05-29 | International Business Machines Corporation | Fabricating product chips and die with a feature pattern that contains information relating to the product chip |
| DK2637672T3 (en) | 2010-11-12 | 2018-10-22 | Gentium S R L | DEFIBROTID FOR USE IN PROPHYLAXY AND / OR TREATMENT OF GRAPHIC VERSUS HOST DISEASE (GVHD) |
| CN110079580B (zh) | 2012-06-22 | 2022-12-06 | 真蒂奥姆责任有限公司 | 用于测定去纤维蛋白多核苷酸的生物活性的基于优球蛋白的方法 |
| EP3026122A1 (en) | 2014-11-27 | 2016-06-01 | Gentium S.p.A. | Cellular-based method for determining the potency of defibrotide |
| SG11202000952PA (en) | 2017-08-03 | 2020-02-27 | Jazz Pharmaceuticals Ireland Ltd | Formulations comprising a nucleic acid in a high concentration |
| MX2020010689A (es) | 2018-04-12 | 2021-01-20 | Jazz Pharmaceuticals Inc | Defibrotida para la prevencion y tratamiento del sindrome de liberacion de citocinas y la neurotoxicidad asociada con la inmunodeplecion. |
| US20220023533A1 (en) | 2018-12-07 | 2022-01-27 | Jazz Phrmaceticals Ireland Limited | Subcutaneous delivery of high concentration formulations |
| US20230190783A1 (en) | 2020-02-28 | 2023-06-22 | Jazz Pharmaceuticals Ireland Limited | Delivery of low viscosity formulations |
| TW202308659A (zh) | 2021-05-06 | 2023-03-01 | 愛爾蘭商爵士製藥愛爾蘭有限責任公司 | 用於急性呼吸窘迫症候群之治療及預防的去纖維蛋白多核苷酸 |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH05247083A (ja) * | 1991-12-09 | 1993-09-24 | Crinos Ind Farmacobiolog Spa | 抗虚血活性を有する新規なオリゴデオキシリボヌクレオチド類およびその製造方法 |
| WO1998048843A1 (en) * | 1997-04-28 | 1998-11-05 | Arsinur Burcoglu | Method of treating hiv infection and related secondary infections thereof |
| DE19740384A1 (de) * | 1997-09-08 | 1999-03-11 | Max Delbrueck Centrum | Antisense Oligodesoxynukleotide (ODN) gegen Proteinkinase C (PKC)-Isoformen, ihre Verwendung und pharmazeutische Zubereitungen dieser ODN |
| US5919772A (en) * | 1993-12-01 | 1999-07-06 | Mcgill University | Antisense oligonucleotides having tumorigenicity-inhibiting activity |
| JP2002512508A (ja) * | 1997-05-30 | 2002-04-23 | マクギル・ユニヴァーシティ | Ｄｎａメチルトランスフェラーゼゲノミック配列およびアンチセンスオリゴヌクレオチド |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2154279A1 (de) * | 1970-11-03 | 1972-05-25 | Crinos Industria Farmaco | Medikamente für das fibrinolytische System |
| IT1043823B (it) * | 1970-11-03 | 1980-02-29 | Prephar | Procedimento per l estrazione di acidi nucleici da organi animali |
| US3899481A (en) * | 1970-11-03 | 1975-08-12 | Crinos Industria Farmaco | Process for the controlled partial degradation of deoxyribonucleic acid extracted from animal organs |
| IT1170214B (it) * | 1983-09-12 | 1987-06-03 | Crinos Industria Farmaco | Composizione farmaceutica per la cura delle arteriopatie periferiche |
| IT1206341B (it) * | 1984-02-16 | 1989-04-14 | Crinos Industria Farmaco | Composizione farmaceutica per il trattamento dell'ischemia acuta del miocardio. |
| US4694134A (en) * | 1985-05-28 | 1987-09-15 | Ajax Magnethermic Corporation | Apparatus for overheating edges of skelp for the production of compression welded pipe |
| US5223609A (en) * | 1986-04-17 | 1993-06-29 | Crinos Industria Farmacobiologica S.P.A. | Process for obtaining chemically defined and reproducible polydeoxyribonucleotides |
| IT1190313B (it) * | 1986-04-17 | 1988-02-16 | Crinos Industria Farmaco | Procedimento per l'ottenimento di polidesossiribonucleotidi chimicamente definiti e riproducibili e prodotto farmacologicamente attivo risultante |
| US6699985B2 (en) * | 1991-08-21 | 2004-03-02 | Arsinur Burcoglu | Method of treating HIV infection and related secondary infections thereof |
| US5977083A (en) * | 1991-08-21 | 1999-11-02 | Burcoglu; Arsinur | Method for using polynucleotides, oligonucleotides and derivatives thereof to treat various disease states |
| US7514414B2 (en) * | 2001-09-24 | 2009-04-07 | The United States Of America As Represented By The Department Of Health And Human Services | Suppressors of CpG oligonucleotides and methods of use |
| ITMI20031714A1 (it) * | 2003-09-05 | 2005-03-06 | Gentium Spa | Formazioni ad azione antitumorale. |
-
2006
- 2006-02-27 JP JP2007557486A patent/JP2008531647A/ja active Pending
- 2006-02-27 CA CA002598613A patent/CA2598613A1/en not_active Abandoned
- 2006-02-27 JP JP2007557485A patent/JP5714203B2/ja not_active Expired - Fee Related
- 2006-02-27 US US11/817,572 patent/US20080194506A1/en not_active Abandoned
- 2006-02-27 WO PCT/EP2006/060306 patent/WO2006094917A2/en not_active Ceased
- 2006-02-27 KR KR1020077023861A patent/KR20070121001A/ko not_active Withdrawn
- 2006-02-27 EP EP06708536A patent/EP1853277A1/en not_active Ceased
- 2006-02-27 AU AU2006222044A patent/AU2006222044A1/en not_active Abandoned
- 2006-02-27 KR KR1020077021114A patent/KR20070120954A/ko not_active Withdrawn
- 2006-02-27 US US11/817,575 patent/US20080194507A1/en not_active Abandoned
- 2006-02-27 AU AU2006222045A patent/AU2006222045B2/en not_active Ceased
- 2006-02-27 MX MX2007010754A patent/MX2007010754A/es not_active Application Discontinuation
- 2006-02-27 EP EP06708537A patent/EP1855697A2/en not_active Withdrawn
- 2006-02-27 WO PCT/EP2006/060304 patent/WO2006094916A1/en not_active Ceased
- 2006-02-27 KR KR1020077021110A patent/KR20070120953A/ko not_active Withdrawn
- 2006-02-27 MX MX2007010407A patent/MX2007010407A/es not_active Application Discontinuation
- 2006-02-27 CA CA2598072A patent/CA2598072C/en not_active Expired - Fee Related
-
2007
- 2007-08-09 IL IL185182A patent/IL185182A0/en active IP Right Grant
- 2007-08-09 IL IL185181A patent/IL185181A0/en unknown
- 2007-08-14 IL IL185258A patent/IL185258A/en unknown
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH05247083A (ja) * | 1991-12-09 | 1993-09-24 | Crinos Ind Farmacobiolog Spa | 抗虚血活性を有する新規なオリゴデオキシリボヌクレオチド類およびその製造方法 |
| US5919772A (en) * | 1993-12-01 | 1999-07-06 | Mcgill University | Antisense oligonucleotides having tumorigenicity-inhibiting activity |
| WO1998048843A1 (en) * | 1997-04-28 | 1998-11-05 | Arsinur Burcoglu | Method of treating hiv infection and related secondary infections thereof |
| JP2002512508A (ja) * | 1997-05-30 | 2002-04-23 | マクギル・ユニヴァーシティ | Ｄｎａメチルトランスフェラーゼゲノミック配列およびアンチセンスオリゴヌクレオチド |
| DE19740384A1 (de) * | 1997-09-08 | 1999-03-11 | Max Delbrueck Centrum | Antisense Oligodesoxynukleotide (ODN) gegen Proteinkinase C (PKC)-Isoformen, ihre Verwendung und pharmazeutische Zubereitungen dieser ODN |
Also Published As
| Publication number | Publication date |
|---|---|
| CA2598072A1 (en) | 2006-09-14 |
| US20080194506A1 (en) | 2008-08-14 |
| AU2006222044A1 (en) | 2006-09-14 |
| EP1855697A2 (en) | 2007-11-21 |
| AU2006222045A1 (en) | 2006-09-14 |
| IL185182A0 (en) | 2008-01-20 |
| JP2008531646A (ja) | 2008-08-14 |
| IL185258A0 (en) | 2008-02-09 |
| WO2006094917A3 (en) | 2006-12-14 |
| EP1853277A1 (en) | 2007-11-14 |
| KR20070120953A (ko) | 2007-12-26 |
| US20080194507A1 (en) | 2008-08-14 |
| JP5714203B2 (ja) | 2015-05-07 |
| CA2598613A1 (en) | 2006-09-14 |
| WO2006094916A1 (en) | 2006-09-14 |
| IL185258A (en) | 2010-12-30 |
| WO2006094917A2 (en) | 2006-09-14 |
| WO2006094917A8 (en) | 2008-01-31 |
| IL185181A0 (en) | 2008-01-20 |
| KR20070121001A (ko) | 2007-12-26 |
| MX2007010754A (es) | 2007-11-07 |
| MX2007010407A (es) | 2007-10-17 |
| KR20070120954A (ko) | 2007-12-26 |
| AU2006222045B2 (en) | 2011-10-20 |
| CA2598072C (en) | 2016-05-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Hou et al. | TREM2 sustains macrophage-hepatocyte metabolic coordination in nonalcoholic fatty liver disease and sepsis | |
| Schlundt et al. | Macrophages in bone fracture healing: their essential role in endochondral ossification | |
| Carlson et al. | Cardiac macrophages adopt profibrotic/M2 phenotype in infarcted hearts: Role of urokinase plasminogen activator | |
| Yoshida et al. | p53-Induced inflammation exacerbates cardiac dysfunction during pressure overload | |
| Armstrong et al. | A phase II trial of temsirolimus in men with castration-resistant metastatic prostate cancer | |
| JP5714203B2 (ja) | 血管新生依存性腫瘍を治療するためのデフィブロチドおよび／またはオリゴデオキシリボヌクレオチド | |
| Xu et al. | Rosuvastatin treatment activates JAK-STAT pathway and increases efficacy of allogeneic mesenchymal stem cell transplantation in infarcted hearts | |
| Feng et al. | EGFL7 is an intercellular EGFR signal messenger that plays an oncogenic role in glioma | |
| EP4012023B1 (en) | Stem cell therapy in endometrial pathologies | |
| EA016653B1 (ru) | Способы и композиции для ингибирования ангиогенеза | |
| Klein et al. | Endothelial Caveolin-1 regulates the radiation response of epithelial prostate tumors | |
| Delfan et al. | High-intensity interval training improves cardiac function by miR-206 dependent HSP60 induction in diabetic rats | |
| JP2024133372A (ja) | 心不全の治療方法 | |
| Segaliny et al. | Combinatorial targeting of cancer bone metastasis using mRNA engineered stem cells | |
| Pidala et al. | Ixazomib for treatment of refractory chronic graft-versus-host disease: a chronic GVHD consortium phase II trial | |
| Ren et al. | Migration-inducing gene-7 independently predicts poor prognosis of human osteosarcoma and is associated with vasculogenic mimicry | |
| KR20200016163A (ko) | 사멸화 세포 처리 대식 세포 유래 엑소좀을 포함하는 암 예방 또는 치료용 조성물 | |
| Vogt et al. | Blockade of angio-associated migratory cell protein inhibits smooth muscle cell migration and neointima formation in accelerated atherosclerosis | |
| Chung et al. | Antibody to interleukin-6 receptor inhibits in vivo growth of human colorectal carcinoma cell xenografts | |
| Fedorchuk et al. | Paraneoplastic syndrome in mice bearing high-angiogenic variant of Lewis lung carcinoma: relations with tumor derived VEGF | |
| Wang et al. | Pigment epithelium-derived factor prevents endothelial dysfunction in early stage of hyperlipidemia by regulating endothelial fatty acid transport | |
| Kang et al. | EGFL7 is an intercellular EGFR signal messenger that plays an oncogenic role in glioma | |
| Ketteler | Role of Caveolin-1 for modulating the radiation response in the context of tumor stroma interactions | |
| Xiao et al. | Layered double hydroxide-delivered si-NEAT1 inhibits breast cancer immune evasion and malignant progression by modulating the miR-141–3p/PD-L1 axis | |
| Stein | Investigating the role of Wnt-pathway inhibition in mouse breast cancer tumor growth and metastasis. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20090212 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20090212 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20120210 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20120509 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20120516 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20120608 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20120615 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20120709 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20120717 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120803 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20130509 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20130730 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20130806 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20130906 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20130913 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20131009 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20131011 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20140512 |